Bacopa monnieri: evidence depends on the extract, amount and population
Human research has examined specific Bacopa preparations and cognitive outcomes. The evidence is not a blanket endorsement of every Bacopa-containing supplement.
Three findings worth keeping separate
Selected memory outcomes
A 2012 systematic review included six 12-week trials using different Bacopa extracts, generally 300–450 mg/day, and found improvement in some memory free-recall tests. Other cognitive domains were less studied.
Low-quality broader evidence
A 2023 systematic review of herbal and nutritional medicines reported that most included studies had high risk of bias, limiting confidence in cognitive conclusions.
Very-low-certainty evidence
A 2022 review found no established treatment difference and rated the evidence very low certainty. Bacopa must not be promoted as preventing or treating Alzheimer disease.
What must match before mapping evidence to a product
Plant identity and plant part should be explicit.
Powder and standardized extract records are not interchangeable.
A commercial serving must be compared with the studied preparation without guessing.
Evidence sources
- Pase et al., 2012Systematic review of randomized controlled trials in adults without dementia or significant cognitive impairment.
- McPhee et al., 2023Systematic review in older adults; low-quality evidence overall because of risk of bias.
- Basheer et al., 2022Systematic review in Alzheimer disease; very-low-certainty evidence and no established treatment conclusion.